Join
Live feed
·
PRReleasevia Quantisnow
Calliditas Therapeutics AB logo

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
CALT· Calliditas Therapeutics AB
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CALT (Calliditas Therapeutics AB) and more on Quantisnow.